TORONTO, ONTARIO–(Marketwire – Aug. 21, 2012) – Arch Biopartners Inc (“Arch”) (CNSX:ACH)(OTCBB:FOIFF) today announced Arch scientists have successfully used magnetic resonance imaging (“MRI”) to detect human brain tumour initiating cells in mice using Arch’s proprietary cell targeting technology.
Brain tumour initiating cells (known as “BTICs”) are believed to be the disease reservoirs of malignant glioma, which escape clinical intervention. Until now these cells were not visible using current diagnostic imaging techniques.
Malignant glioma is one of the deadliest brain cancers. The average patient with malignant glioma has a life expectancy of approximately 1 year and “long-term survivors” (i.e. surviving ≥ 3 years) are rare. The main cause of death is recurrence of tumours post-therapy, which is believed to result from undetected and untreated disease reservoirs.
Arch anticipates that the imaging of BTICs will lead to improvements in the surgical and therapeutic management of brain tumours.
A longer term objective is to adapt Arch’s proprietary targeting molecules to deliver anti-cancer drugs directly to BTICs and other brain cancer cells.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.
Arch is developing non-invasive diagnostic and therapeutic molecules for brain cancer through its fully owned subsidiary, Arch Cancer Therapeutics (“ACT”). These molecules are specialized peptides proprietary to ACT that target and identify BTICs and invasive brain cancer cells that are not normally seen using current diagnostic imaging techniques.
For more information on Arch, please consult the other public documents filed on SEDAR at www.sedar.com.
The company’s website address is: www.archbiopartners.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of Arch. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Arch assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.